Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
62 (26%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-LEVOCARB | 25MG 250MG | TABLET | Resolved | 2019-02-06 | 2019-03-01 | 74911 |
| APO-LEVOCARB | 25MG 250MG | TABLET | Resolved | 2020-12-28 | 2021-02-22 | 130710 |
| APO-LEVOCARB | 25MG 250MG | TABLET | Resolved | 2021-03-26 | 2021-05-10 | 136403 |
| APO-LEVOCARB | 25MG 250MG | TABLET | Resolved | 2017-10-03 | 2017-11-09 | 24265 |
| APO-LEVOCARB | 25MG 100MG | TABLET | Resolved | 2018-01-17 | 2018-02-27 | 36298 |
| APO-LEVOCARB | 25MG 100MG | TABLET | Resolved | 2019-02-06 | 2019-02-25 | 74894 |
| APO-LEVOCARB | 25MG 100MG | TABLET | Resolved | 2019-02-06 | 2019-02-25 | 74896 |
| APO-LEVOCARB | 25MG 100MG | TABLET | Resolved | 2020-09-09 | 2020-09-21 | 123939 |
| APO-LEVOCARB | 25MG 100MG | TABLET | Resolved | 2021-02-19 | 2021-03-15 | 134436 |
| APO-LEVOCARB | 25MG 100MG | TABLET | Resolved | 2021-02-26 | 2021-03-08 | 134817 |
| APO-LEVOCARB | 100MG 25MG | TABLET | Resolved | 2024-08-15 | 2024-10-04 | 235339 |
| APO-LEVOCARB | 25MG 100MG | TABLET | Resolved | 2020-06-10 | 2020-08-05 | 117390 |
| APO-LEVOCARB | 100MG 25MG | TABLET | Resolved | 2023-01-26 | 2023-03-30 | 182364 |
| APO-LEVOCARB | 100MG 25MG | TABLET | Resolved | 2023-03-23 | 2023-04-06 | 187718 |
| APO-LEVOCARB | 100MG 25MG | TABLET | Resolved | 2023-04-14 | 2023-05-06 | 189632 |
| APO-LEVOCARB | 100MG 25MG | TABLET | Resolved | 2022-05-06 | 2022-05-19 | 160138 |
| APO-LEVOFLOXACIN | 750MG | TABLET | Resolved | 2022-06-17 | 2022-07-28 | 162907 |
| APO-LEVOFLOXACIN | 250MG | TABLET | Resolved | 2022-07-15 | 2023-01-20 | 164719 |
| APO-LEVOFLOXACIN | 500MG | TABLET | Resolved | 2022-07-15 | 2022-08-06 | 164728 |
| APO-LEVOFLOXACIN | 500MG | TABLET | Resolved | 2022-09-30 | 2023-01-20 | 170766 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |